Item Type | Name |
Concept
|
Anemia, Iron-Deficiency
|
Concept
|
Anemia
|
Academic Article
|
Complications of chronic kidney disease: anemia, mineral metabolism, and cardiovascular disease.
|
Academic Article
|
Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease.
|
Academic Article
|
The benefits of IV iron therapy in treating anemia in patients with renal disease and comorbid cardiovascular disease.
|
Academic Article
|
Uncertainty in the treatment of anemia in chronic kidney disease.
|
Academic Article
|
Correction of anemia with epoetin alfa in chronic kidney disease.
|
Academic Article
|
The target hemoglobin in patients with chronic kidney disease.
|
Academic Article
|
Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.
|
Academic Article
|
Anaemia of CKD--the CHOIR study revisited.
|
Academic Article
|
The FDA black box for EPO: what should nephrologists do?
|
Academic Article
|
Anemia of chronic kidney disease: CHOIR and the FDA.
|
Academic Article
|
Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease.
|
Academic Article
|
Does correction of anemia slow the progression of chronic kidney disease?
|
Academic Article
|
Is it time to reconsider subcutaneous administration of epoetin?
|
Academic Article
|
Anemia of chronic kidney disease.
|
Academic Article
|
Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin.
|
Academic Article
|
The optimal hemoglobin in dialysis patients- a critical review.
|
Academic Article
|
Managing anemia in dialysis patients: hemoglobin cycling and overshoot.
|
Academic Article
|
Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease.
|
Academic Article
|
Iron deficiency in non-dialysis chronic kidney disease.
|
Academic Article
|
Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes.
|
Academic Article
|
Hemoglobin target in chronic kidney disease: a pediatric perspective.
|
Academic Article
|
Endothelial activation markers in anemic non-dialysis chronic kidney disease patients.
|
Academic Article
|
The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
|
Academic Article
|
Ferric gluconate treatment provides cost savings in patients with high ferritin and low transferrin saturation.
|
Academic Article
|
Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
|
Academic Article
|
Posttransplant anemia: the role of sirolimus.
|
Academic Article
|
Resolved: Targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia: pro.
|
Academic Article
|
Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization.
|
Academic Article
|
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
|
Academic Article
|
A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment.
|
Academic Article
|
Does TREAT give the boot to ESAs in the treatment of CKD anemia?
|
Academic Article
|
The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis.
|
Academic Article
|
ESAs in dialysis patients: are you a hedgehog or a fox?
|
Academic Article
|
Debate: PRO Position. Should hemoglobin targets for anemic patients with chronic kidney disease be changed?
|
Academic Article
|
Diabetes, anemia and CKD: Why TREAT?
|
Academic Article
|
The etiology of anemia in heart failure. Preface.
|
Academic Article
|
Therapy with erythropoiesis-stimulating agents and renal and nonrenal outcomes.
|
Academic Article
|
Anemia in chronic kidney disease: new advances.
|
Academic Article
|
What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level?
|
Academic Article
|
Erythropoietic response and outcomes in kidney disease and type 2 diabetes.
|
Academic Article
|
Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience.
|
Academic Article
|
Modulation of platelet activation in chronic kidney disease patients on erythropoiesis-stimulating agents.
|
Academic Article
|
Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial.
|
Academic Article
|
Anaemia: Does the KDIGO guideline move the needle in CKD anaemia?
|
Academic Article
|
Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
|
Academic Article
|
Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease.
|
Academic Article
|
How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The itsy bitsy anemia problem.
|
Academic Article
|
Prevalence of vitamin D deficiency in Saudi adults.
|
Academic Article
|
Ferric pyrophosphate citrate (Triferic?) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients.
|
Academic Article
|
A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease.
|
Academic Article
|
Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial.
|
Academic Article
|
Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
|
Academic Article
|
Prolyl-hydroxylase inhibitors for the treatment of anemia in chronic kidney disease.
|
Academic Article
|
Colonic Polypoid Arteriovenous Malformation Causing Symptomatic Anemia.
|
Academic Article
|
Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial.
|
Academic Article
|
Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.
|
Academic Article
|
Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis.
|
Academic Article
|
The ASCEND-ND trial: study design and participant characteristics.
|
Academic Article
|
Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial.
|
Academic Article
|
Debate: Are HIF Stabilizers a Viable Alternative to ESAs in the Management of Anemia in CKD? PRO.
|
Academic Article
|
Daprodustat and On-Treatment Cardiovascular Events in Chronic Kidney Disease. Reply.
|
Academic Article
|
Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D).
|
Academic Article
|
Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial.
|